keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/29474196/adenocarcinoma-prostate-with-neuroendocrine-differentiation-potential-utility-of-18f-fdg-pet-ct-and-68ga-dotanoc-pet-ct-over-68ga-psma-pet-ct
#1
Girish Kumar Parida, Sarthak Tripathy, Shreya Datta Gupta, Abhinav Singhal, Rakesh Kumar, Chandrasekhar Bal, Shamim Ahmed Shamim
Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-DOTANOC PET/CT and F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-PSMA PET/CT imaging and benefit of Ga-DOTANOC PET/CT and F-FDG PET/CT in such cases...
February 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29468311/-68-ga-psma-pet-ct-imaging-of-localized-primary-prostate-cancer-patients-for-intensity-modulated-radiation-therapy-treatment-planning-with-integrated-boost
#2
Lena Thomas, Steffi Kantz, Arthur Hung, Debra Monaco, Florian C Gaertner, Markus Essler, Holger Strunk, Wolfram Laub, Ralph A Bundschuh
PURPOSE: The purpose of our study was to show the feasibility and potential benefits of using68 Ga-PSMA-PET/CT imaging for radiation therapy treatment planning of patients with primary prostate cancer using either integrated boost on the PET-positive volume or localized treatment of the PET-positive volume. The potential gain of such an approach, the improvement of tumor control, and reduction of the dose to organs-at-risk at the same time was analyzed using the QUANTEC biological model...
February 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29465494/68ga-psma-pet-ct-revealing-unusual-inguinal-canal-and-distant-nodal-metastasis-in-a-case-of-castration-resistant-prostate-cancer
#3
Shelvin Kumar Vadi, Rajender Kumar, Bhagwant Rai Mittal, Harmandeep Singh, Shrawan Kumar Singh
Gallium-prostate-specific membrane antigen (Ga-PSMA) is well established in the imaging of prostate cancer (PC). Here, we report a case of castration-resistant PC who underwent Ga-PSMA PET/CT for recurrence evaluation, which revealed metastatic lesions in distant lymph nodes and additionally an unusual metastatic deposit in the inguinal canal. The second Ga-PSMA PET/CT done after oral hormonal therapy yielded a favorable response. This pattern of distant metastatic spread is a rare presentation of PC, and PSMA PET/CT revealed the unusual metastasis in the inguinal canal with a timely therapy culminating in favorable disease response...
February 21, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29465493/unusual-case-of-diffuse-penile-metastasis-of-prostate-cancer-on-68ga-psma-pet-ct-imaging-and-177lu-psma-posttherapy-scintigraphy
#4
Shelvin Kumar Vadi, Rajender Kumar, Bhagwant Rai Mittal, Ashwin Singh Parihar, Shrawan Kumar Singh
An 85-year-old man with prostate cancer for metastatic workup underwent Gallium Prostate-Specific Membrane Antigen (Ga-PSMA) PET/CT (Ga-PSMA PET/CT), which revealed unusual tracer uptake in the shaft and glans of penis as well as multiple systemic metastases in liver, skeletal, and lymph nodes. The penile lesion was proved to be metastatic adenocarcinoma from prostate on fine needle aspiration cytology. The patient underwent Lutetium (Lu)-labeled PSMA radioligand therapy, which also revealed diffuse tracer uptake in the penile shaft as well as other metastatic sites...
February 21, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29465489/small-lymph-node-metastasis-detected-by-68ga-prostate-specific-membrane-antigen-but-not-18f-fluciclovine-pet-ct-in-low-prostate-specific-antigen-biochemical-recurrence-of-prostate-cancer
#5
Guillaume Chaussé, Gad Abikhzer, Stephan Probst
A 58-year-old man with Gleason 4+3 prostate cancer was initially treated by radical prostatectomy followed by salvage radiotherapy to the prostate bed for postoperative biochemical failure. One year later, F-fluorocholine PET/CT detected a pelvic lymph node recurrence, which was treated with radiation therapy and 6 months of androgen deprivation. PSA started to rise again 18 months later, but F-fluciclovine PET/CT failed to demonstrate the site of recurrence at a PSA of 0.63 ng/mL. However, Ga-PSMA PET/CT revealed a single positive 4-mm perirectal lymph node (PSA 0...
February 21, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29465429/advances-in-prostate-specific-membrane-antigen-pet-of-prostate-cancer
#6
Kirsten Bouchelouche, Peter L Choyke
PURPOSE OF REVIEW: In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCa). This review highlights advances in PSMA PET in PCa during the past year. RECENT FINDINGS: PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCa, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI)...
February 19, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29460025/combined-model-based-and-patient-specific-dosimetry-for-18-f-dcfpyl-a-psma-targeted-pet-agent
#7
Donika Plyku, Esther Mena, Steven P Rowe, Martin A Lodge, Zsolt Szabo, Steve Y Cho, Martin G Pomper, George Sgouros, Robert F Hobbs
PURPOSE: Prostate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for18 F-DCFPyL in nine patients with metastatic prostate cancer. METHODS: Nine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8...
February 19, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29459281/synthesis-and-evaluation-of-a-novel-urea-based-68-ga-complex-for-imaging-psma-binding-in-tumor
#8
Zhihao Zha, Karl Ploessl, Seok Rye Choi, Zehui Wu, Lin Zhu, Hank F Kung
INTRODUCTION: Prostate specific membrane antigen (PSMA) is a well-established target for diagnostic and therapeutic applications for prostate cancer. It is know that [68 Ga]PSMA 11 ([68 Ga]Glu-NH-CO-NH-Lys(Ahx)-HBED-CC) is the most well studied PET imaging agent for detecting over expressed PSMA binding sites of tumors in humans. In an effort to provide new agents with improved characteristics for PET imaging, we report a novel [68 Ga]-Glu-NH-CO-NH-Lys(Ahx)-linker-HBED-CC conjugate with a novel O-(carboxymethyl)-L-tyrosine, as the linker group...
December 27, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29455299/prostate-specific-membrane-antigen-in-breast-cancer-a-comprehensive-evaluation-of-expression-and-a-case-report-of-radionuclide-therapy
#9
Yuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, Aydan Koyun, Daniela Huber, Christina Kehrer, Thomas Hecking, Mignon-Denise Keyver-Paik, Christina Kaiser, Hojjat Ahmadzadehfar, Markus Essler, Walther Kuhn, Glen Kristiansen
PURPOSE: Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized. METHODS: This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29454548/correlation-between-molecular-tumor-volume-evaluated-with-68-ga-psma-pet-ct-and-prostatic-specific-antigen-levels
#10
S Medina-Ornelas Sevastián, O García-Pérez Francisco, Y Hernández-Pedro Norma, E Arellano-Zarate Angélica, L Abúndiz-López Blanca
OBJECTIVE: To investigate the association between prostatic-specific antigen (PSA) levels and molecular tumor volume (MTV) measured in the68 Ga-PSMA PET/CT, both done in a short period of time, in prostate cancer patients with biochemical failure. METHODS: Eighty-four patients who underwent68 Ga-PSMA PET/CT and measurement of PSA levels in the same week (trigger-PSA) were studied in this retrospective analysis. MTV was calculated from the sum of the metastatic lesions...
February 14, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29445927/advantage-of-18-f-psma-1007-over-68-ga-psma-11-pet-imaging-for-differentiation-of-local-recurrence-vs-urinary-tracer-excretion
#11
Kambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, Michael Schäfers, Lars Stegger, Martin Bögemann
No abstract text is available yet for this article.
February 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29439481/review-of-gallium-68-psma-pet-ct-imaging-in-the-management-of-prostate-cancer
#12
REVIEW
Nat P Lenzo, Danielle Meyrick, J Harvey Turner
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68 Ga-PSMA-positron emission tomography/computed tomography ( 68 Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68 Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach...
February 11, 2018: Diagnostics
https://www.readbyqxmd.com/read/29434370/imaging-predicting-68ga-psma-pet-ct-positivity-for-recurrent-disease
#13
Louise Stone
No abstract text is available yet for this article.
February 13, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29432341/rare-case-of-intratracheal-metastasis-detected-on-68ga-prostate-specific-membrane-antigen-pet-ct-scan-in-a-case-of-thyroglobulin-elevated-negative-iodine-scan-syndrome
#14
Arun Sasikumar, Ajith Joy, M R A Pillai, Karuna Elza Oommen, R Jayakumar
A 64-year-old woman underwent completion thyroidectomy with upper tracheal ring resection and right-sided neck dissection for papillary carcinoma of the thyroid infiltrating the trachea and was given I radioiodine treatment. Three years later, she presented with hemoptysis. On evaluation, she had increased serum thyroglobulin and negative iodine scan (TENIS). F-FDG PET/CT scan did not identify any site of disease. One year later, Ga-PSMA scan done revealed a moderate focal tracer-avid intratracheal soft tissue; biopsy revealed it to be metastatic papillary carcinoma of the thyroid...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29430118/penile-metastasis-from-prostate-cancer-presenting-as-malignant-priapism-detected-using-gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography
#15
Koramadai Karuppusamy Kamaleshwaran, Barani Kumar Pollachi Balasundararaj, Raghi Jose, Ajit Sugunan Shinto
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-68 PSMA PET/CT) is a promising diagnostic tool for patients with prostate cancer. Penile metastasis from prostate cancer is a rare phenomenon that infrequently manifests as malignant priapism. We present a case of 79-year-old patient diagnosed as a case of adenocarcinoma prostate presenting with penile metastases imaged using Ga-68 PSMA PET/CT.
January 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29422356/will-68ga-psma-radioligands-be-the-only-choice-for-nuclear-medicine-in-prostate-cancer-in-the-near-future-a-clinical-update
#16
V Cuccurullo, G D di Stasio, L Evangelista, A Ciarmiello, L Mansi
Prostate Cancer (PCa) represents the most common malignant tumor in men but according to the European Association of Urology (EAU) guidelines, a mass screening for PCa diagnosis should not be performed due to over-diagnosis and over-treatment related problems. An early clinical diagnosis is possible, mainly based on digital rectal examination and Prostatic Specific Agent (PSA) testing. However, the only mandatory test to define the presence of PCa is ultrasound guided-biopsy, obtained on multiple samples, which has also a high prognostic value...
February 5, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29419475/biochemical-recurrence-of-prostate-cancer-initial-results-with-18f-psma-1007-pet-ct
#17
Frederik Giesel, Leon Will, Claudia Kesch, Martin Freitag, Christophe Kremer, Jonas Merkle, Oliver Neels, Jens Cardinale, Boris Hadaschik, Markus Hohenfellner, Klaus Kopka, Uwe Haberkorn, Clemens Kratochwil
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labelled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labelled ligands were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent positron emission tomography/computed tomography (PET/CT) scans 1h and 3h after injection (p...
February 1, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29411076/solitary-testicular-metastasis-from-prostate-cancer-a-case-report-diagnosed-by-pet-ct-with-psma
#18
Marcelo Livorsi da Cunha, Camila de Oliveira Rodrigues, Mariana Petruccelli Lima de Araújo, Celso Heitor de Freitas Junior, Robson Ferrigno
No abstract text is available yet for this article.
February 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29409824/68ga-psma-pet-ct-for-primary-diagnosis-of-prostate-cancer-in-men-with-contraindications-to-or-negative-mpmri-a-prospective-observational-study
#19
Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale
BACKGROUND: 68Ga-PSMA PET/CT may represent the most promising imaging modality for identification and risk stratification of prostate cancer (PCa) in patients with contraindications to or negative multiparametric MRI (mpMRI). METHODS: This prospective observational study analyzed 68Ga-PSMA PET/CT in a selected group of patients with persistently elevated PSA and/or PHI (prostate health index) suspicious for PCa, negative digital rectal examination, and at least one negative biopsy...
January 31, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29401152/prostate-specific-membrane-antigen-pet-ct-incidental-finding-of-a-schwannoma
#20
André H Dias, Kirsten Bouchelouche
We describe a case of a 73-year-old man with newly diagnosed prostate cancer referred to Ga-PSMA PET/CT for staging. A focal uptake of PSMA was visualized in the prostate compatible with primary prostate cancer. Outside the prostate, a PSMA-avid paravertebral soft tissue mass was observed. Further investigation with MRI of the same region showed signs compatible with schwannoma. This case shows the importance of including schwannoma in the differential diagnostic evaluation of patients with Ga-PSMA-positive foci in paravertebral locations, as schwannomas may show avid PSMA uptake and may potentially lead to an incorrect diagnosis of metastasis...
February 3, 2018: Clinical Nuclear Medicine
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"